Challenges and Implications of Trump’s Vaccine Order

Public health experts have criticized an executive order from President Donald Trump. The order targets childhood vaccinations in the U.S.

The order calls for separating combination vaccines like the measles, mumps, and rubella (MMR) vaccine into individual injections. It also suggests spacing out vaccination appointments.

Financial and Logistical Hurdles

Implementing this order presents significant financial and logistical challenges. Drug manufacturers would need to revive individual vaccines that have not been used for decades. This would require constructing new manufacturing facilities to accommodate the increased demand for vaccine doses.

For parents, unbundling the MMR vaccine means more frequent doctor visits. This could add strain to pediatricians and increase costs for medical supplies.

Scientific Consensus and Public Health Policy

Studies show that combination vaccines increase the likelihood of complete vaccination against infectious diseases before school age. Health experts note there is no scientific basis for Trump’s changes. Dr. Anna Durbin, from Johns Hopkins Bloomberg School of Public Health, states, “There is no good justification for this. I think it’s very bad public health policy.”

Manufacturing Challenges

The order demands federal plans for separating and spacing vaccinations within 90 days. However, industry experts believe these changes would take years. There is no current market for individual vaccines for measles, mumps, or rubella in the U.S.

According to Dr. Jesse Goodman, a former FDA vaccine chief, manufacturers may need extensive studies to ensure immune response effectiveness. This includes safety assessments for new manufacturing procedures.

Pediatrician and Parental Concerns

Breaking up the MMR shot means six doctor visits instead of two. Additional spacing of other shots could exacerbate the issue. Dr. Durbin warns this may result in fewer vaccinations. Parents might struggle to keep up with the increased appointment schedule.

Historically, Trump has argued that American children receive too many vaccines. He suggests smaller doses over longer periods. Some officials have pointed to Denmark, which recommends fewer vaccinations.

Legal and Industry Implications

Trump’s order lacks legal authority. Neither the White House nor the FDA can compel vaccine manufacturers to create new vaccines. Companies have little financial incentive to develop individual vaccines when combination shots are already profitable.

Some believe state governments, responsible for vaccination laws for schoolchildren, will ignore the executive order, choosing public health guidelines over presidential advisement.

“I think states will ignore this,” said Dr. Paul Offit, a vaccine researcher. He emphasizes the importance of following scientific consensus over presidential directives.

The Associated Press Health and Science Department continues to report on immunization efforts. Their coverage is supported by the Howard Hughes Medical Institute and the Robert Wood Johnson Foundation.